Knowledge Library
Biophysical and Structural Biology Methods Enable Fragment-Based Ligand Discovery
Powerful biophysical and structural biology tools enable the study of large numbers of fragments and are opening new possibilities in the treatment of various diseases. In this webinar, WuXi AppTec presents the results of a conventional and covalent fragment-based drug discovery screen, and our expert speaker discusses how orthogonal biophysical and structural methods enable the …Read More >
Discovery of RNA Targeting Small Molecules – Our Toolbox for RNA Drug Discovery
Drug Discovery Chemistry Conference 2023 WuXi AppTec has developed technologies to facilitate RNA small molecule screening, an exciting frontier in drug discovery. SHAPE-MaP is applied to determine RNA structure and dynamics and verify small molecule binding. We utilize the “DNA-Zipper” strategy to enable DNA-encoded libraries to identify RNA binders. With other technologies including fragment-based drug …Read More >
Biophysical and Structural Biology Methods Enable Fragment-based Covalent Ligand Discovery of Human BTK
Drug Discovery Chemistry Conference 2023 Powerful biophysical and structural biology tools enable the study of large numbers of covalent fragments and are opening up new possibilities in the treatment of various diseases. Here, Dr. Moran Jerabek-Willemsen, Head of Biophysics & Screening in WuXi Biology reports the results of a covalent FBDD project on Bruton’s Tyrosine …Read More >
Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit GID4
Expansion of the E3 ligase toolbox has the potential to dramatically advance the field of targeted protein degradation. WuXi AppTec scientists recently contributed to a research article in the Journal of Medicinal Chemistry describing the discovery of novel small molecule binders of GID4, a substrate receptor in the human CTLH E3 ligase complex. Researchers used …Read More >
Introduction into Fragment Based Drug Discovery
Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification in the drug discovery process. Fragments are small molecules with a low molecular weight, smaller than lead molecules or druglike molecules. The FBDD technology is based on identifying small chemical fragments, which bind to the biological target …Read More >
WuXi AppTec Discovery Services
Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.
Drug Discovery: Screening Approaches for Rapid Assessment of Target Tractability
Optimizing Drug Pipelines With Biophysical Methods
Download our whitepaper on how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle. Discover fresh opportunities to characterize challenging drug targets, examine biophysical screening methods, and look toward what’s next for biophysical methods in drug discovery.
One-Stop Target-to-Hit Solutions
WuXi AppTec | Target-to-Hit Solutions Protein Production | All Target Classes and Challenging Proteins Biophysical & Biochemical Platforms | Ready-To-Go Assay for Broad Range of Drug Targets Structural Biology Platforms Fragment Library & Screening ~3100 “Rule of three” compliant fragments
